Navigation Links
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis

aries; refer to the individual country product label for complete information. For U.S. safety information, visit http://www.HUMIRA.com.

Serious infections, sepsis, rare cases of tuberculosis (TB), and opportunistic infections, including fatalities, have been reported with the use of TNF antagonists, including HUMIRA. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their RA could predispose them to infections. Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections.

TNF-blocking agents have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of the virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating HUMIRA.

The combination of HUMIRA and anakinra is not recommended.

TNF antagonists, including HUMIRA, have been associated in rare cases with demyelinating disease and serious allergic reactions. Rare reports of pancytopenia including aplastic anemia have been reported with TNF-blocking agents. Adverse events of the haematologic system, including medically significant cytopenia have been infrequently reported with HUMIRA.

'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
Post Your Comments:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising Phase 1/2 ... mda-7/IL-24 tumor,suppressor agent, in patients with advanced solid ... today at the,annual meeting of the American Society ... INGN 241 induced killing in all treated,tumors, including ...
... Company Planning to Initiate Phase 2 Trials ... in Q307 -, SOUTH SAN FRANCISCO, Calif., ... , a,biopharmaceutical company focused on oncology, today ... of two Phase 1,dose-escalating trials of picoplatin, ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Kan., Jan. 28 Fort Dodge Animal Health,a ... the American Association of Equine,Practitioners (AAEP) recently announced ... raise awareness regarding the health of horses.,Americashealthyhorse.com provides ... The America,s Healthy Horse Web site will aide ...
... -- The Cystic Fibrosis Foundation reported today that key ... including lung function and nutritional status -- are rising ... fact, the outlook for people with CF continues to ... accelerating due to quality improvement programs spearheaded by the ...
... To support,Pennsylvanians who made a New Year,s resolution ... announced that Governor Edward G.,Rendell has proclaimed Jan. 28 ... "Determined to Quit Week is all about motivating Pennsylvanians ... Secretary of,Health Dr. Calvin B. Johnson. "For anyone who ...
... to Expand Profile with Area Representatives, TAMPA, ... leading study program, announces a new program to ... Area,Representatives will travel to massage schools nationwide to ... so comprehensive that,Massage Prep guarantees passage of the ...
... ... Presenting at the UBS Global Healthcare Services Conference on Tuesday, ... February 12, 2008, CINCINNATI, Jan. ... the,LasikPlus brand, announced today upcoming investment community events., Fourth Quarter & Full-Year 2007 ...
... Russian women who smoke has more than doubled since the ... In 1992, seven per cent of women smoked, compared to ... the number of men who smoke has risen from 57 ... the study, published in the journal Tobacco Control, blame the ...
Cached Medicine News:Health News:Fort Dodge Animal Health and the American Association of Equine Practitioners Launch Educational Web Site 2Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
... provides surgeons with brighter, crisper, magnified views ... for many minimally invasive spine procedures. It ... point of contact. The first graphical touchscreen ... allows intuitive user guidance similar to that ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: